Project Grant R03CA292991
Award Date 7/9/24
Completion Date 7/8/26
Dollars Obligated $158K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80014, USA
Similar Awards
- Federal Grant Award Summary Massachusetts General Hospital (The General Hospital Corporation) received a $429,399 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period September 1, 2025 through August 31, 2027. The award supports the recalibration of the Lung Cancer Policy Model (LCPM) to address critical limitations in how the model estimates the effectiveness and cost-effectiveness of low-dose computed tomography...
- The National Cancer Institute awarded a $1.68M Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to Kaiser Foundation Hospitals to develop and implement evidence-based strategies for expanding lung cancer screening in Federally Qualified Health Centers (FQHCs). The award, dated September 12, 2025, with an ultimate completion date of August 31, 2027, supports the EXHALE (Expanding Lung Cancer Screening to Achieve Excellence) initiative,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University in St. Louis a Project Grant totaling $425,088 (Award Date: May 1, 2026; Completion Date: April 30, 2031) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a comparative analysis of lung cancer care and outcomes between Medicare Advantage (MA) and Traditional Medicare (TM) beneficiaries. The research project will leverage large national databases to create...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $2.99 million Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 23, 2025, with completion targeted for August 31, 2029. The award funds a research initiative to characterize trends and outcomes of lung cancer screening (LCS) among people with HIV (PWH) in the United States, addressing a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Cereus Diagnostics Corp. $764,448 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test for detecting clinically actionable lung cancer mutations. The three-year project, effective August 1, 2025 through July 31, 2028, will deliver a clinical-grade...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Institute For Cancer Research a Project Grant of $766,439 under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period April 1, 2026 through March 31, 2031. This research project focuses on intratumor heterogeneity as a correlate of clinical outcomes in bladder cancer patients pursuing cystectomy avoidance strategies. The primary deliverables include: (1) scientific investigation into the genetic...
- Federal Grant Award Summary The National Cancer Institute awarded a $409,141 Project Grant to the University of California, Davis, effective June 1, 2026, through May 31, 2028, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). The grant supports research and development of perfusion computed tomography (CT) imaging technology as an alternative diagnostic tool for liver radioembolization treatment planning. The project aims to validate contrast-enhanced perfusion CT as a...